EMA – Page 10 – Pharma.Tips

Non-clinical toxicity findings during IND-enabling studies – FDA/EMA non-clinical expectations

Addressing Non-clinical Toxicity Concerns in IND-Enabling Studies Non-clinical toxicity findings during IND-enabling studies can pose significant challenges to drug development. These findings can jeopardize the acceptance of Investigational New Drug…

GLP readiness concerns during program hold risk review – regulatory deficiency risk analysis

Addressing GLP Readiness Issues During Program Hold Risk Review for Regulatory Compliance In the fast-paced environment of pharmaceutical development, ensuring compliance with Good Laboratory Practices (GLP) is imperative, especially during…

Species selection questioned during study audit – how to defend preclinical package

“`html Addressing Species Selection Concerns During Preclinical Study Audits In the competitive landscape of pharmaceutical research and drug development, regulatory audits can raise critical questions, particularly around the choice of…

Target validation uncertainty during regulatory interaction preparation – risk mitigation strategy

Mitigating Target Validation Uncertainty for Regulatory Interactions in Drug Development In recent years, the landscape of drug development has become increasingly complex, particularly concerning target validation during regulatory interactions. When…

Reproducibility issues in screening data during early discovery – risk mitigation strategy

“`html Investigating Reproducibility Issues in Screening Data During Early Discovery As pharmaceutical professionals navigate the complexities of early drug discovery, reproducibility issues can significantly hinder progress, particularly during preclinical studies.…

Target validation uncertainty during translational assessment – data package strengthening approach

Mitigating Target Validation Uncertainty in Translational Assessment: An Investigative Approach In drug discovery and development, effectively handling target validation uncertainty during translational assessments is critical. As pharmaceutical professionals, encountering deviations,…

ADME liabilities identified late during early discovery – impact on IND success probability

Exploring Late Identification of ADME Liabilities in Early Discovery and its Impact on IND Success In the highly regulated field of pharmaceutical development, late identification of Absorption, Distribution, Metabolism, and…

ADME liabilities identified late before IND-enabling studies – data package strengthening approach

Addressing Late-Identified ADME Liabilities Before IND-Enabling Studies The identification of Absorption, Distribution, Metabolism, and Excretion (ADME) liabilities at an advanced stage in drug development can lead to significant regulatory challenges…

Off-target toxicity signals before IND-enabling studies – risk mitigation strategy

Identifying and Mitigating Off-Target Toxicity Signals Prior to IND-Enabling Studies In the complex landscape of pharmaceutical development, identifying off-target toxicity signals before initiating Investigational New Drug (IND)-enabling studies is critical…

Tag: EMA